Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376: 1211-1222.

Published: 26th April 2017

Authors: Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Bayer-Westendorf J, Bounameaux H et al.

Conclusion

Some 3396 patients who completed their initial anticoagulation were randomized to aspirin or rivaroxaban for a further twelve months. Recurrent symptomatic venous thromboembolism was more common in patients on aspirin: 4.4 versus 1.5 per cent on 20mg and 1.2 per cent on 10mg rivaroxaban (P<0.001 for both doses). Major bleeding rates were similar.

Pubmed Link

Your comments

0 Comments